Methods of treatment of tuberous sclerosis complex

A method of treating a medical condition associated with tuberous sclerosis complex (TSC), comprising administering to a subject in need thereof a composition comprising a therapeutically effective amount of a pharmaceutically acceptable salt of a compound of Formula I, wherein the compound of Formula I has the structure:

• and wherein the pharmaceutically acceptable salt comprises a crystalline anhydrate form (Form A) of a monosulfate salt of the compound of Formula I, wherein the crystalline anhydrate form (Form A) is characterized by at least three peaks selected from the following X-ray powder diffraction peaks obtained with a CuKα radiation at 2θ (2 Theta):
• 9.8±0.2°, 13.4±0.2°, 14.2±0.2°, 18.1±0.2°, 18.9±0.2°, 19.6±0.2°, 22.6±0.2°, 22.9±0.2°, 25.7±0.2°, 27.1±0.2°, and 29.9±0.2°.